@article{22795,
  author = {Mrkobrada M. and Garg A. and Devereaux P. and Walsh M. and Thabane L. and Lee V. and Chow Clara and Roshanov P. and MacNeil S. and Lam N. and Hildebrand A. and Acedillo R.},
  title = {External validation of the Revised Cardiac Risk Index and update of its renal variable to predict 30-day risk of major cardiac complications after non-cardiac surgery: rationale and plan for analyses of the VISION study},
  abstract = {<p>
INTRODUCTION: The Revised Cardiac Risk Index (RCRI) is a popular classification system to estimate patients' risk of postoperative cardiac complications based on preoperative risk factors. Renal impairment, defined as serum creatinine &gt;2.0 mg/dL (177 micromol/L), is a component of the RCRI. The estimated glomerular filtration rate has become accepted as a more accurate indicator of renal function. We will externally validate the RCRI in a modern cohort of patients undergoing non-cardiac surgery and update its renal component. METHODS AND ANALYSIS: The Vascular Events in Non-cardiac Surgery Patients Cohort Evaluation (VISION) study is an international prospective cohort study. In this prespecified secondary analysis of VISION, we will test the risk estimation performance of the RCRI in approximately 34 000 participants who underwent elective non-cardiac surgery between 2007 and 2013 from 29 hospitals in 15 countries. Using data from the first 20 000 eligible participants (the derivation set), we will derive an optimal threshold for dichotomising preoperative renal function quantified using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) glomerular filtration rate estimating equation in a manner that preserves the original structure of the RCRI. We will also develop a continuous risk estimating equation integrating age and CKD-Epi with existing RCRI risk factors. In the remaining (approximately) 14 000 participants, we will compare the risk estimation for cardiac complications of the original RCRI to this modified version. Cardiac complications will include 30-day non-fatal myocardial infarction, non-fatal cardiac arrest and death due to cardiac causes. We have examined an early sample to estimate the number of events and the distribution of predictors and missing data, but have not seen the validation data at the time of writing. ETHICS AND DISSEMINATION: The research ethics board at each site approved the VISION protocol prior to recruitment. We will publish our results and make our models available online at http://www.perioperativerisk.com. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT00512109.
</p>
},
  year = {2017},
  journal = {BMJ Open},
  volume = {7},
  edition = {2017/01/11},
  number = {1},
  pages = {e013510},
  isbn = {2044-6055 (Electronic)<br/>2044-6055 (Linking)},
  note = {Roshanov, Pavel S<br/>Walsh, Michael<br/>Devereaux, P J<br/>MacNeil, S Danielle<br/>Lam, Ngan N<br/>Hildebrand, Ainslie M<br/>Acedillo, Rey R<br/>Mrkobrada, Marko<br/>Chow, Clara K<br/>Lee, Vincent W<br/>Thabane, Lehana<br/>Garg, Amit X<br/>K23 GM087534/GM/NIGMS NIH HHS/United States<br/>UL1 RR024992/RR/NCRR NIH HHS/United States<br/>England<br/>BMJ Open. 2017 Jan 9;7(1):e013510. doi: 10.1136/bmjopen-2016-013510.},
  language = {eng},
}